Compare Amgen, Inc. (AMGN) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Coursera Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Coursera Inc trades at $5.71 (market cap $1.64B). The key difference: Amgen, Inc. is far larger — about 119.6× Coursera Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| AMGN | COUR | |
|---|---|---|
Market Cap | $196.12B | $1.64B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $12.70 |
52-Week Low | $271.18 | $5.09 |
Enterprise Value | $241.41B | $890.21M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Coursera (COUR) trades at $5.71, up 0.71% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $757.5M in 2025, though net losses persist at -$51M. The Udemy merger and a $500M share repurchase program are key developments. Cash flow from operations remains positive at $108.7M, supporting ongoing investments.
Wall Street analysts are generally optimistic with a $8.00 consensus price target, implying 40% upside. Risks include sustained profitability challenges and integration execution post-merger. The stock presents a growth opportunity if operational synergies materialize, but investors should weigh the high volatility and competitive pressures in edtech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
